echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > "Pharmaceutical headliner" anti-aging drug young death drug supervision officials were sentenced to bribery.

    "Pharmaceutical headliner" anti-aging drug young death drug supervision officials were sentenced to bribery.

    • Last Update: 2020-09-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    (2020/08/17) Total value of more than $6 billion! Gilead and Tango expand their oncology strategy; 41 companies with a market capitalisation of more than $900 billion have broken the ice; how to lead the medical industry; and the capital chain is broken! Another big hospital went bankrupt... (Click on the title to get the original text) The total value of Medicine 1st Time is over $6 billion! Gilead and Tango's Expanded Oncology Strategy Partnership On August 17, local time, Gilead and Tango Therapeutics announced an expanded strategic partnership to identify, develop and commercialize innovative immunologic escape therapies targeted at cancer patients, with candidate products valued at up to $6 billion.
    : This collaboration has produced two preclinical candidates.
    the first 2 billion retail respiratory drugs were born! China Resources, Tai Chi... Leading the 30 billion market, Ering Pharmaceuticals announced that Lianhua Qing plague capsules have been approved for sale in Kyrgyzstan, through the pharmacy network and store counters.
    the first quarter of this year, Lianhua Qing plague products revenue of more than 1.5 billion yuan.
    china's urban retail pharmacies have seen steady growth in the market for chinese medicine respiratory diseases in recent years, with sales exceeding the 30 billion mark in 2019, according to the company's internal network data.
    : Cold spirit particles in recent years in China's urban retail pharmacy sales growth.
    (Xinhua) -- The early death of an anti-aging drug today Unity, a pioneer in the development of new anti-aging drugs in the United States, announced that its main product, UBX0101, failed to beat a placebo in a 183-person Osteoarthritis Phase II clinic.
    the trial's first-level endpoint was a 12-week WOMMAC-A score, and the results showed not only that UBX0101 was no different from a placebo, but also did not show a meaningful effect relationship, and in fact only the lowest dose showed a certain trend in efficacy.
    unity announced that it would abandon the development of the product, and that other drugs for senescing cells would continue, but these are preclinical assets.
    the news, Unity dived 60 percent today.
    : OA has a hard time in the pain-relief market.
    the development and prospect of "gene magic shear" technology CRISPR/Cas9, a star technology, has been in the public eye since its inception in 2002.
    the technology was named one of Science's Top 10 Scientific Breakthroughs in 2012, 2013 and 2015, and was named one of the top ten most influential technologies of the 21st century by the media, as well as a strong contender for the Nobel Prize.
    : Gene technology is moving in the direction of continuous precision and safety.
    days before dandelion drug regulatory officials were sentenced to death for taking bribes, Dandelion published an article on "The Director of the Review and Certification Center of a Provincial Bureau, Sentenced to 5 Years".
    , a former director of the Gansu Provincial Drug Administration's Review and Certification Center, was criminally detained on suspicion of corruption and bribery and sentenced to five years in prison at first instance and a fine of 400,000 yuan.
    headlines: Hard to escape the French Open.
    the total market value of more than 900 billion 41 enterprises break the science and technology board how to lead the medical industry long-distance voyage? Unlike fast-moving, financial, catering and other industries, medical care is a "slow" industry.
    A medical enterprise from its inception to the market, need to go through products, policies, technology testing, especially drug research and development and high-end medical device manufacturing two sub-areas, from product design, clinical trials, to approval, marketing, the whole process of several years, which is faced with product iteration risk, clinical trial failure risk, market risk ... Every risk is enough to break the cash flow of start-ups and die out.
    : Kotson is still some time away from maturity.
    see the medical profession, the funding chain is broken! Another large hospital went bankrupt recently, Hong Kong-listed Huahan Health (00587) issued a notice, the Hong Kong court on August 4 issued its winding-up regulations, its indirectly owned hospital six sets of water cool people's hospital declared bankruptcy reorganization.
    : Listed companies need to be cautious about transforming healthcare.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.